
MBX Stock Forecast & Price Target
MBX Analyst Ratings
Bulls say
MBX Biosciences is attractive because its PEP platform is already generating clinical signals that support differentiated dosing convenience and pharmacology, with canvuparatide showing mean serum calcium in range through one year, lower urinary calcium, and about a 1.3 peak-to-trough ratio. The weekly PTH opportunity also appears commercially credible, as the company estimates a roughly $1 billion global PTH market, while canvuparatide’s Phase 3 program could remove about 313 injections annually and still leave room alongside Yorvipath given strong retention and open-label rollover. MBX 4291 adds further upside by targeting monthly obesity dosing after four weekly loading doses, with early 7% weight loss data, 12.5% nausea/vomiting/diarrhea in the first MAD cohort, and $418.6 million in cash providing runway into 2029.
Bears say
MBX Biosciences is a clinical-stage biopharmaceutical company with no current commercial product, so its valuation depends almost entirely on unproven pipeline assets and the ability to fund a long development cycle before any sales materialize. Its lead programs still face meaningful clinical and regulatory risk: MBX 4291’s opportunity hinges on sustained weight loss with acceptable GI tolerability, while canvuparatide and earlier-stage programs could require additional trial changes, longer follow-up, more patients, or further manufacturing work, all of which would raise costs and delay approval. Even if approved, the company may struggle with competition, reimbursement pressure, and commercialization execution, and management expects cash flow breakeven only in 2030 or 2031, leaving significant dilution and financing risk if timelines slip.
This aggregate rating is based on analysts' research of MBX Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
MBX Analyst Forecast & Price Prediction
Start investing in MBX
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About MBX Biosciences Inc (MBX) Forecast
MBX Analyst Forecast & Price Prediction
Start investing in MBX
Order type
Buy in
Order amount
Est. shares
0 shares